title: Increased levels of serum basic fibroblast growth factor in schizophrenia.
abstract: Basic fibroblast growth factor (bFGF) is a multifunctional growth factor that has been implicated in a variety of neurodevelopmental processes. The aim of the present study was to examine whether bFGF contributes to the pathophysiology of schizophrenia. Serum bFGF levels in 40 patients with schizophrenia (15 drug-naive and 25 medicated patients) and in 40 age- and sex-matched healthy normal controls were measured. Serum bFGF levels were significantly higher in the medicated patients than in the normal controls. Analysis of partial correlation coefficients showed that the increased bFGF levels might not be attributable to antipsychotic medication. Although there was no significant overall difference in bFGF levels between drug-naive patients and normal controls, the bFGF levels in these patients significantly correlated with the severity of negative symptoms. Furthermore, we found a significant negative correlation between serum bFGF levels and the age of onset in the entire patient group. Our finding of elevated bFGF levels in the serum of patients with schizophrenia, especially in earlier age-of-onset cases considered to have more neurodevelopmental insults, suggests that bFGF abnormalities may be involved in the pathophysiology of schizophrenia.
authors.affiliation: Department of Psychiatry, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chiba 260-8670, Japan. hashimoto@faculty.chiba-u.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Shimizu
authors.forename: Naoya
authors.initials: N
authors.lastname: Komatsu
authors.forename: Michiko
authors.initials: M
authors.lastname: Nakazato
authors.forename: Naoe
authors.initials: N
authors.lastname: Okamura
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Chikara
authors.initials: C
authors.lastname: Kumakiri
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Shinoda
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Okada
authors.forename: Nori
authors.initials: N
authors.lastname: Takei
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001925:Brain Damage, Chronic / Q000097:blood / Q000175:diagnosis / Q000523:psychology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012016:Reference Values; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013223:Statistics as Topic
chemical_list: D014150:Antipsychotic Agents; D016222:Fibroblast Growth Factor 2